STAT

MAY 19, 2024

Removing a patient’s race from an equation used to assess lung function — a change called for by health equity advocates — would mean that the lung disease of nearly half a million Black Americans would be reclassified as being more severe, and that Black veterans could receive more than $1 billion in additional disability payments, according to a study published Sunday in the New England Journal of Medicine.

347

347

Pharmacy Joe

MAY 19, 2024

In this episode, I’ll discuss if phentolamine the only thing you can use for vasopressor extravasation. Episode 923: Is phentolamine the only thing you can use for vasopressor extravasation? Subscribe on iTunes , Android , or Stitcher Extravasation is a complication of IV therapy that refers to the infiltration of tissues with a medication that is an irritant or vesicant.

Inpatient 98

Inpatient Hospitals 98

Drug Patent Watch

MAY 19, 2024

ADASUVE (loxapine) Alexza pharms Patent: 9,370,629 Expiration: May 20, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.

59

59

FDA Law Blog: Biosimilars

MAY 19, 2024

By Sarah Wicks — On May 21, 2024, the EveryLife Foundation for Rare Diseases (ELF) will host a Scientific Workshop at the National Press Club in Washington, D.C. aimed at identifying and characterizing the challenges in developing therapies for ultra-rare diseases and conditions that affect exceedingly small populations. The workshop will drive in-depth discussions from leaders across federal agencies, the patient advocacy community, industry, academia and policy to examine the current state of

Drug Development 59

Drug Development 59

Speaker: Joe Sharpe and James Carlson

In the world of small business management, the challenge of managing payroll & HR efficiently while scaling operations can be overwhelming. Yet, with the right strategies in place, these challenges can become opportunities for growth and innovation. In this session, Joe Sharpe, Senior Director of Managed Payroll Services at IRIS, will reveal practical methods and expert insights for outsourcing and streamlining payroll processes, resulting in substantial time and resource savings.

Drug Patent Watch

MAY 19, 2024

Annual Drug Patent Expirations for ADASUVE Adasuve is a drug marketed by Alexza Pharms and is included in one NDA. It is available from one supplier.

59

59

Pharmaceutical Technology

MAY 19, 2024

Discover what industry professionals seek in contract manufacturing for parenteral solutions. Ensure quality, compliance, and innovation with our comprehensive guide. Click to learn more.

52

52

Express Pharma

MAY 19, 2024

Life science research and development in India is increasing substantially, driven by a combination of government initiatives, a skilled workforce, and continued investments. The COVID-19 pandemic has further elevated the significance of this industry, spotlighting India’s role as a major global player in vaccine production and pharmaceutical R&D.

Vaccines 52

Vaccines Pharmaceutical Manufacturing 52

Med Ed 101

MAY 19, 2024

Thiazide diuretics are commonly are one of the most commonly used classes of antihypertensive agents. They carry many adverse effects. Some can be a nuisance while others can be more serious. In this blog post, I’ll run down the most common thiazide diuretic adverse effects to be aware of. Urinary Frequency I would classify urinary […] The post Top 5 Thiazide Diuretic Adverse Effects appeared first on Med Ed 101.

52

52

The Guardian - Pharmaceutical Industry

MAY 19, 2024

Our desires are an essential part of who we are – as I discovered when I lost my appetite for six months Mostly, walking down New York streets in spring sunshine is the cinematic, euphoric ideal of what it is to be alive. It’s the thing I looked forward to for decades. It meant to me, back then as a kid in Ireland, listening to songs about Lexington and 14th Street, freedom: an almost deranged amount of freedom.

54

54

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction.

52

52

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

Pharmacy Times

MAY 19, 2024

Researchers observed that patients aged 80 years and older with acute myeloid leukemia who were treated with venetoclax and a hypomethylating agent had prolonged overall survival.

49

49

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

52

52

Drug Patent Watch

MAY 19, 2024

This chart shows the pharmaceutical companies with the most patents in Lithuania.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies 59

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Metastatic Biliary Tract Cancer.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Metastatic Pancreatic Cancer.

52

52

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Renal Cell Carcinoma.

52

52

Pharmaceutical Technology

MAY 19, 2024

Olverembatinib is under clinical development by Ascentage Pharma Group International and currently in Phase II for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia).

40

40

Pharmaceutical Technology

MAY 19, 2024

Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma).

40

40

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction.

40

40

Pharmaceutical Technology

MAY 19, 2024

Furmonertinib mesylate is under clinical development by Shanghai Allist Pharmaceuticals and currently in Phase II for Lung Adenocarcinoma.

40

40

Pharmaceutical Technology

MAY 19, 2024

Elixcyte is under clinical development by Unicocell Biomed and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure).

40

40

Pharmaceutical Technology

MAY 19, 2024

Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Neuroblastoma.

40

40

Pharmaceutical Technology

MAY 19, 2024

Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Osteosarcoma.

40

40

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

40

40

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Metastatic Biliary Tract Cancer.

40

40

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Metastatic Pancreatic Cancer.

40

40

Pharmaceutical Technology

MAY 19, 2024

Vusolimogene oderparepvec is under clinical development by Replimune and currently in Phase II for Metastatic Melanoma.

40

40

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Malignant Mesothelioma.

40

40

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Renal Cell Carcinoma.

40

40

Pharmaceutical Technology

MAY 19, 2024

Dipraglurant is under clinical development by Addex Therapeutics and currently in Phase II for Blepharospasm.

40

40

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Cervical Cancer.

40

40

Pharmaceutical Technology

MAY 19, 2024

PLX-038 is under clinical development by ProLynx and currently in Phase II for Recurrent Medulloblastoma.

40

40

Pharmaceutical Technology

MAY 19, 2024

SkinTE is under clinical development by RegenETP and currently in Phase III for Diabetic Foot Ulcers.

Diabetes 40

Diabetes 40